FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3047128064> ?p ?o ?g. }

• W3047128064 endingPage "3277" @default.
• W3047128064 startingPage "3269" @default.
• W3047128064 abstract "Abstract Background Clofazimine is in widespread use as a key component of drug-resistant TB regimens, but the recommended dose is not evidence based. Pharmacokinetic data from relevant patient populations are needed to inform dose optimization. Objectives To determine clofazimine exposure, evaluate covariate effects on variability, and simulate exposures for different dosing strategies in South African TB patients. Patients and methods Clinical and pharmacokinetic data were obtained from participants with pulmonary TB enrolled in two studies with intensive and sparse sampling for up to 6 months. Plasma concentrations were measured by LC-MS/MS and interpreted with non-linear mixed-effects modelling. Body size descriptors and other potential covariates were tested on pharmacokinetic parameters. We simulated different dosing regimens to safely shorten time to average daily concentration above a putative target concentration of 0.25 mg/L. Results We analysed 1570 clofazimine concentrations from 139 participants; 79 (57%) had drug-resistant TB and 54 (39%) were HIV infected. Clofazimine pharmacokinetics were well characterized by a three-compartment model. Clearance was 11.5 L/h and peripheral volume 10 500 L for a typical participant. Lower plasma exposures were observed in women during the first few months of treatment, explained by higher body fat fraction. Model-based simulations estimated that a loading dose of 200 mg daily for 2 weeks would achieve average daily concentrations above a target efficacy concentration 37 days earlier in a typical TB participant. Conclusions Clofazimine was widely distributed with a long elimination half-life. Disposition was strongly influenced by body fat content, with potential dosing implications for women with TB." @default.
• W3047128064 created "2020-08-10" @default.
• W3047128064 creator A5000612367 @default.
• W3047128064 creator A5009435222 @default.
• W3047128064 creator A5015227985 @default.
• W3047128064 creator A5018480886 @default.
• W3047128064 creator A5027219518 @default.
• W3047128064 creator A5028037547 @default.
• W3047128064 creator A5030734346 @default.
• W3047128064 creator A5034322602 @default.
• W3047128064 creator A5053945845 @default.
• W3047128064 creator A5056892721 @default.
• W3047128064 creator A5068645131 @default.
• W3047128064 creator A5090394540 @default.
• W3047128064 date "2020-08-03" @default.
• W3047128064 modified "2023-10-16" @default.
• W3047128064 title "Clofazimine pharmacokinetics in patients with TB: dosing implications" @default.
• W3047128064 cites W105671925 @default.
• W3047128064 cites W1414898727 @default.
• W3047128064 cites W1675359132 @default.
• W3047128064 cites W1968368454 @default.
• W3047128064 cites W1989525615 @default.
• W3047128064 cites W2006583270 @default.
• W3047128064 cites W2012174175 @default.
• W3047128064 cites W2076472674 @default.
• W3047128064 cites W2096040265 @default.
• W3047128064 cites W2114292367 @default.
• W3047128064 cites W2120416054 @default.
• W3047128064 cites W2125159822 @default.
• W3047128064 cites W2132116629 @default.
• W3047128064 cites W2136094138 @default.
• W3047128064 cites W2242069468 @default.
• W3047128064 cites W2291779966 @default.
• W3047128064 cites W2409413489 @default.
• W3047128064 cites W2417159818 @default.
• W3047128064 cites W2532501510 @default.
• W3047128064 cites W2534216031 @default.
• W3047128064 cites W2546418571 @default.
• W3047128064 cites W2603525203 @default.
• W3047128064 cites W2751465424 @default.
• W3047128064 cites W2933620934 @default.
• W3047128064 cites W2989551129 @default.
• W3047128064 cites W95153707 @default.
• W3047128064 doi "https://doi.org/10.1093/jac/dkaa310" @default.
• W3047128064 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7566350" @default.
• W3047128064 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32747933" @default.
• W3047128064 hasPublicationYear "2020" @default.
• W3047128064 type Work @default.
• W3047128064 sameAs 3047128064 @default.
• W3047128064 citedByCount "23" @default.
• W3047128064 countsByYear W30471280642020 @default.
• W3047128064 countsByYear W30471280642021 @default.
• W3047128064 countsByYear W30471280642022 @default.
• W3047128064 countsByYear W30471280642023 @default.
• W3047128064 crossrefType "journal-article" @default.
• W3047128064 hasAuthorship W3047128064A5000612367 @default.
• W3047128064 hasAuthorship W3047128064A5009435222 @default.
• W3047128064 hasAuthorship W3047128064A5015227985 @default.
• W3047128064 hasAuthorship W3047128064A5018480886 @default.
• W3047128064 hasAuthorship W3047128064A5027219518 @default.
• W3047128064 hasAuthorship W3047128064A5028037547 @default.
• W3047128064 hasAuthorship W3047128064A5030734346 @default.
• W3047128064 hasAuthorship W3047128064A5034322602 @default.
• W3047128064 hasAuthorship W3047128064A5053945845 @default.
• W3047128064 hasAuthorship W3047128064A5056892721 @default.
• W3047128064 hasAuthorship W3047128064A5068645131 @default.
• W3047128064 hasAuthorship W3047128064A5090394540 @default.
• W3047128064 hasBestOaLocation W30471280641 @default.
• W3047128064 hasConcept C105795698 @default.
• W3047128064 hasConcept C112705442 @default.
• W3047128064 hasConcept C119043178 @default.
• W3047128064 hasConcept C126322002 @default.
• W3047128064 hasConcept C139254425 @default.
• W3047128064 hasConcept C203014093 @default.
• W3047128064 hasConcept C2776297342 @default.
• W3047128064 hasConcept C2777288759 @default.
• W3047128064 hasConcept C2780695269 @default.
• W3047128064 hasConcept C33923547 @default.
• W3047128064 hasConcept C71924100 @default.
• W3047128064 hasConcept C98274493 @default.
• W3047128064 hasConceptScore W3047128064C105795698 @default.
• W3047128064 hasConceptScore W3047128064C112705442 @default.
• W3047128064 hasConceptScore W3047128064C119043178 @default.
• W3047128064 hasConceptScore W3047128064C126322002 @default.
• W3047128064 hasConceptScore W3047128064C139254425 @default.
• W3047128064 hasConceptScore W3047128064C203014093 @default.
• W3047128064 hasConceptScore W3047128064C2776297342 @default.
• W3047128064 hasConceptScore W3047128064C2777288759 @default.
• W3047128064 hasConceptScore W3047128064C2780695269 @default.
• W3047128064 hasConceptScore W3047128064C33923547 @default.
• W3047128064 hasConceptScore W3047128064C71924100 @default.
• W3047128064 hasConceptScore W3047128064C98274493 @default.
• W3047128064 hasFunder F4320306137 @default.
• W3047128064 hasFunder F4320310966 @default.
• W3047128064 hasFunder F4320311904 @default.
• W3047128064 hasFunder F4320320671 @default.
• W3047128064 hasFunder F4320320939 @default.
• W3047128064 hasFunder F4320332161 @default.

• next